Mortalidad por infarto del miocardio en chile. Tromboliticos o angioplastia.

Autores/as

  • Fernando Florenzano U Departamento de Medicina Oriente, Universidad de Chile.Clínica Las Condes.

Palabras clave:

Angioplasty, Myocardial infarction, Survival rate, Thrombolytic therapy

Resumen

Mortality after myocardial infarction.  Thrombolytic therapy or angioplasty.

During the recent decades, acute myocardial infarction short-term mortality has decreased to one digit levels, in the United States. Data from Chilean registries give figures around 11% for thrombolysis, and between 5 to 6 % for angioplasty. The decrease in mortality is related to the implementation of the AUGE program at a national level, initiative than gives to the public the opportunity to receive at least thrombolytic therapy as well as a standarized and rapid diagnosis and treatment for this condition. There is a lack of Outcome Research studies in our country,  that would help to take public health decisions such as the use of fibrin-specific agents for early presentation and high risk cases, and a rational system for having better access to primary angioplasty.    

 

Biografía del autor/a

Fernando Florenzano U, Departamento de Medicina Oriente, Universidad de Chile.Clínica Las Condes.

Departamento de Medicina Oriente, Universidad de Chile. Clínica Las Condes.

Publicado

2011-10-19

Cómo citar

Florenzano U, F. (2011). Mortalidad por infarto del miocardio en chile. Tromboliticos o angioplastia. Revista Médica De Chile, 139(11). Recuperado a partir de https://revistamedicadechile.cl/index.php/rmedica/article/view/1730